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Abstract: Genomic disorders are a clinically diverse group of conditions caused by gain, loss or re-orientation of a ge-
nomic region containing dosage-sensitive genes. One class of genomic disorder is caused by hemizygous deletions result-
ing in haploinsufficiency of a single or, more usually, several genes. For example, the heterozygous contiguous gene dele-
tion on chromosome 22q11.2 causing DiGeorge syndrome involves at least 20-30 genes. Determining how the copy num-
ber variation (CNV) affects human variation and contributes to the aetiology and progression of various genomic disor-
ders represents important questions for the future. Here, I will discuss the functional significance of one form of CNV, 
haploinsufficiency (i.e. loss of a gene copy), of DNA damage response components and its association with certain ge-
nomic disorders. There is increasing evidence that haploinsufficiency for certain genes encoding key players in the cells 
response to DNA damage, particularly those of the Ataxia Telangiectasia and Rad3-related (ATR)-pathway, has a func-
tional impact. I will review this evidence and present examples of some well known clinically similar genomic disorders 
that have recently been shown to be defective in the ATR-dependent DNA damage response. Finally, I will discuss the 
potential implications of a haploinsufficiency-induced defective DNA damage response for the clinical management of 
certain human genomic disorders. 
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1. INTRODUCTION 
  It has long been appreciated that changes in gene copy 
number are associated with phenotypes in humans. Perhaps, 
the most well known example of this is the trisomy 21 causa-
tive of Down syndrome. Here, increased expression of the 
genes on chromosome 21 results directly or indirectly in a 
clinically heterogeneous disorder incorporating cognitive 
impairment, facial dysmorphology, growth retardation, can-
cer predisposition, microcephaly, heart and skeletal abnor-
malities [1]. Interestingly, it was recently shown that CNV is 
in fact a common genetic trait in clinically unaffected or 
‘normal’ individuals [2]. Indeed, the first complete genomic 
sequence from an individual, the so-called ‘Venter genome’ 
yielded a surprising level of CNV, highlighting the plasticity 
of the human genome [3]. The phenomenal recent revolution 
in the sensitivity and widespread usage of array-based Com-
parative Genomic Hybridization (array-CGH/a-CGH) tech-
niques has led to CNV being described as the ‘Breakthrough 
of the Year’ by the journal Science [4]. The widespread use 
of a-CGH has facilitated the description of several novel 
genomic disorders and aided in the detailed genetic charac-
terisation of known genomic disorders. A persistent chal-
lenge to clinical geneticists and researchers is to unravel ex-
actly how changes in CNV of specific genes or various com-
binations of genes can impact on normal development. These  
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issues have recently been extensively reviewed elsewhere 
and the reader is directed to these sources for an overview of 
a-CGH technology and its applications [5-12]. Here, I will 
discuss the potential role of haploinsufficiency of DNA 
damage response components, particularly that of the ATR-
pathway, in genomic disorders. Contiguous gene deletion 
disorders represent a clinically diverse group of human ge-
nomic disorders caused by distinct heterozygous chromoso-
mal deletions usually involving several genes [5, 13]. It is 
assumed that the various clinical manifestations of different 
genomic disorders arise from the combined impact of hap-
loinsufficiency of multiple genes [14]. It is likely that there 
are critical genes or pathways sensitive to haploinsufficiency 
either alone or when combined with haploinsufficiency of 
other genes. There is increasing evidence from both human 
and murine studies suggestive of a cellular impact of hap-
loinsufficiency of genes that control different aspects of the 
response to DNA damage. Since our genomes are constantly 
exposed to exogenously-derived (e.g. UV radiation) and 
endogenously-derived (e.g. metabolically generated reactive 
oxygen species) DNA damaging agents, an impaired ability 
to detect and/or respond appropriately to these threats can 
impact on the maintenance of genetic stability. There are 
many examples of human Mendelian disorders defective in 
the repair of or response to DNA damage [15]. The impor-
tance of these pathways is demonstrated by the increase in 
cancer predisposition and developmental abnormalities asso-
ciated with these conditions [15]. An important DNA dam-
age response (DDR) pathway that appears to be affected by 
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2. THE ATR-DEPENDENT DNA DAMAGE RE-
SPONSE (ATR-DDR) 
  The DDR can be divided into DNA repair processes and 
signal transduction processes that sense DNA damage and 
co-ordinate the appropriate response such as cell cycle 
checkpoint activation, DNA repair and/or apoptosis. Two 
phosphoinositol-3-kinase-like protein kinases (PIKK) co-
ordinate the signal transduction response to DNA damage in 
mammalian cells [16-18]. Ataxia Telangiectasia Mutated 
(ATM) is activated following DNA double strand breaks 
(DSBs) whilst a related kinase, Ataxia Telangiectasia and 
Rad3-related (ATR), responds to single stranded regions of 
DNA. Single stranded DNA (ssDNA) can act as an interme-
diate during the activity of several excision-mediated repair 
pathways (nucleotide excision repair and base excision re-
pair), during uncoupling of the transcriptional machinery 
from its DNA template or similarly following stalling of the 
DNA replication machinery at DNA lesions or single strand 
breaks. Following the exposure of ssDNA, it is quickly 
coated by RPA, a heterotrimeric protein complex (RPA1-3) 
that plays a role in many aspects of DNA metabolism (e.g. 
replication, repair, transcription). ATR is recruited to the 
ssDNA via its binding partner ATRIP (ATR Interacting Pro-
tein) [19, 20]. Topoisomerase binding protein 1 (TopBP1) 
appears to be required for optimal ATR kinase activity [21]. 
Phosphorylation of the histone H2A variant H2AX on Ser-
139 (called -H2AX) is one of the earliest detectable PIKK-
dependent responses to DNA damage and is required for the 
retention of additional damage response proteins at the dam-
age site [22-24]. The Mre11/Rad50/NBS1 complex, the 
Rad17/Rfc2-5 and Rad9/Rad1/Hus1 complexes are recruited 
to the site of damage independently of ATR/ATRIP and are 
also phosphorylated by ATR [25, 26]. Retention of these 
complexes facilitates ATR’s ability to phosphorylate down-
stream substrates including Brca1, p53 and its effector 
kinase Chk1 [15].  
  There is a large amount of functional overlap between 
ATM and ATR. In fact, both kinase’s phosphorylate mainly 
the same substrates in response to DNA damage (e.g. Mre11/ 
Rad50/NBS1 complex, p53, Brca1). DSBs can undergo exo- 
nucleolytic resection generating ssDNA overhangs, hence 
generating an ATR activating substrate [27]. Conversely, 
ssDNA generated at stalled replication forks can collapse 
producing overt DSBs, hence generating an ATM activating 
substrate [28]. Nevertheless, congenital defects in ATM and 
ATR are associated with clinically distinct human disorders. 
Mutations in ATM cause Ataxia telangiectasia, a progressive 
degenerative neurological disorder characterised by ataxia 
and lymphoid malignancy predisposition [29, 30]. Mutations 
in ATR result in Seckel syndrome, a disorder characterised 
by microcephaly and growth retardation [31, 32].  
3. ATR AND GENOMIC STABILITY 
  ATR is required to maintain genomic stability. Whilst it 
has a role in the stabilisation of stalled replication forks, the 
absence of ATR results in a very specific type of genomic 
instability, namely DNA Fragile Site expression. DNA Frag-
ile Sites (DFS) are large (>100Kb) distinct genomic regions 
that exhibit breaks under conditions of replicative ‘stress’ 
[33, 34]. Such stresses can be induced in the laboratory using 
DNA replication inhibitors such as aphidicolin or by folate 
deficiency, which can indirectly impact on the availability of 
dNTP’s. There are about 75-80 DFS throughout the human 
genome but it is not really clear why DFS are so unstable. 
Most tend to be relatively AT-rich and contain more areas of 
flexibility than non-fragile site regions. Studies on the repli-
cation timing of certain fragile sites (FRA3B, FRA7H, 
FRAXA on chromosome 3, 7 and X respectively) indicate 
that they are replicated very slowly [33]. DFS are ‘hot spots’ 
for sister chromatid exchanges (SCE’s) and are also thought 
to play a role in gene amplification events via a breakage-
fusion-bridge cycle [33]. Breakage at or ‘expression of’ DFS 
is associated with many cancers. For example, the FHIT tu-
mour suppressor gene spans the DFS FRA3B [35]. This gene 
is often re-arranged or partially deleted in a wide range of 
tumours (lung, ovarian, breast, esophageal) [36]. Pioneering 
work by the Glover laboratory identified ATR as the first 
protein required to mediate DFS stability [37]. Subsequently, 
several other proteins have been implicated in maintaining 
DFS stability including the Brca1, SMC1, WRN helicase, 
Chk1 and the Fanconi anaemia pathway components FANC-
A, FANC-B and FANC-D2 [33, 38-41]. Interestingly, most 
of these proteins are known direct ATR substrates.  
4. SECKEL SYNDROME: AN ATR-PATHWAY DE-
FECTIVE DISORDER 
  Seckel syndrome, originally described as ‘Bird headed 
Dwarfism’ in a 1960 monograph by Dr. Helmut Seckel, is a 
disorder characterised by severe microcephaly, isolated 
skeletal abnormalities (clinodactyly, thoracic kyphosis, ivory 
epiphysis) and a dramatic proportionate primordial dwarfism 
[42]. Microcephaly is a clinical term describing a reduction 
in occipitofrontal (or head) circumference greater than 3 
standard deviations (-3 s.d.) below the age-related mean. 
This reduced head circumference is a consequence of prema-
ture closure and fusion of the cranial sutures reflecting the 
underlying reduction in brain volume. The aetiology of mi-
crocephaly is complex. It can occur in the context of genetic 
(e.g. syndromal) or non-genetic (e.g. intrauterine infection) 
situations. Microcephaly is particularly pronounced in Seckel 
syndrome [31, 42, 43]. The first genetic defect associated 
with Seckel syndrome was described in 2003. A single syn-
onymous hypomorphic mutation in ATR  was identified in 
five affected individuals in two consanguineous Pakistani 
families [31]. The mutation (A21201G) was shown to ad-
versely impact on splicing, resulting in dramatically reduced 
ATR expression in cells derived from the affected patients. 
Gene targeting of ATR in the murine system results in early 
embryonic lethality [44, 45]. Hence, these ATR-defective 
Seckel syndrome cells (ATR-S) proved a useful tractable 
model to investigate ATR-pathway function in the mammal-
ian setting. ATR-S cells exhibited a diminished ability to 
phosphorylate ATR substrates following DNA damage-
induced ATR-pathway activation (e.g. H2AX formation and 
p53-serine-15 phosphorylation) as well as defective cell cy-
cle checkpoint arrest and increased DFS expression [31, 46, 
47].  
  Seckel syndrome is known to be genetically heterogene-
ous [43, 46, 48-50]. Interestingly, Alderton et al. showed that 
several unrelated non-ATR  mutated Seckel syndrome cell 
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failure of ATR-dependent G2-M cell cycle checkpoint arrest) 
[46]. Hence, in agreement with the known genetic heteroge-
neity of this condition, whilst not all Seckel syndrome cases 
are caused by mutations in ATR itself, interestingly, all 
Seckel syndrome cell lines (ATR-S and non-ATR-S) exhibit 
compromised ATR-pathway function [46]. A further inter-
esting cellular feature of ATR-pathway defective Seckel 
cells is supernumerary centrosomes in 10-20% of mitotic 
cells [46]. A normal mitotic cell must only have two centro-
somes that nucleate the microtubule spindles facilitating 
transfer of an equal and identical chromosome complement 
to the daughter cells [51, 52]. The molecular aetiology of 
supernumerary mitotic centrosomes in Seckel syndrome cells 
is currently unclear. Centrosome orientation is fundamental 
for determining symmetric and asymmetric stem cell divi-
sion in the embryonic neuroepithelium, an essential process 
for normal brain development [53-55]. Hence, this cellular 
feature may be a relevant contributor to the severe micro-
cephaly characteristic of Seckel syndrome. Recently, the 
second genetic defect associated with Seckel syndrome was 
described. Mutations in pericentrin (PCNT2)/kendrin which 
encodes a structural centrosomal protein, were identified in 
several Seckel syndrome patients all of which exhibited de-
fective ATR-pathway function [56]. This exciting finding 
further illustrates a functional link between the DDR, the cell 
cycle machinery and the centrosome. Furthermore, mutations 
in PCNT2 were also recently found in several microcephalic 
osteodysplastic primordial dwarfism type II (MOPD II) pa-
tients [57, 58]. Whether PCNT2-mutated Seckel syndrome 
and MOPD II represent distinct disorders or allelic variants 
of the same condition remains an open question. 
5. OTHER DISORDERS THAT EXHIBIT COMPRO-
MISED ATR-PATHWAY FUNCTION 
  Compromised ATR-pathway function does not appear to 
be uniquely associated with Seckel syndrome. Several other 
known DDR disorders have been shown to be defective in 
aspects of ATR-pathway activity, particularly cell cycle 
checkpoint activation. Interestingly, whilst these disorders 
are all characterised by a distinct set of clinical features, 
there is significant clinical overlap with Seckel syndrome, 
particularly concerning the developmental abnormalities 
such as microcephaly and growth retardation (Table 1). 
5.1. Nijmegen Breakage Syndrome (NBS) 
  NBS is caused by hypomorphic mutations in the Nbs1 
component of the Mre11/Rad50/NBS (MRN) complex [59, 
60]. The MRN complex plays a central role in ATM signal-
ling where it is thought to recruit ATM to the DSB and also 
facilitate its ability to phosphorylate substrates such as p53 
and Chk2 [61]. In fact, all the components of this complex 
are ATM substrates. Historically, NBS has been described as 
an A-T-like disorder as cell lines from both conditions ex-
hibit radio-sensitivity and similar cell cycle checkpoint de-
fects in response to DSBs. But, NBS1 is also an ATR sub-
strate and NBS patients exhibit microcephaly and growth 
retardation, clinical features associated with Seckel syn-
drome and not A-T. Recently, NBS cells were shown to be 
compromised for ATR-dependent checkpoint activation and 
other aspects of ATR-pathway function [26]. Therefore, 
NBS represents a human condition defective in elements of 
both ATM and ATR-pathway activity. 
5.2. Fanconi Anaemia (FA) 
  FA, is a genetically heterogeneous condition character-
ised by a progressive aplastic anaemia, skeletal abnormali-
ties, microcephaly and lymphoid malignancy. FA is caused 
by mutations in different genes whose products co-ordinately 
function in the cellular response to DNA cross-links [62, 63]. 
Several of these genes encode products that together mediate 
the monoubiquitylation and activation of the FANC-D2 pro-
tein in response to DNA damage, particularly during S phase 
[62]. ATR and NBS1 have been shown to be required for 
this specific modification [64-66]. In fact, ATR-S and NBS 
patient-derived cell lines fail to monoubiquitylate FANC-D2 
following treatment with replication fork inhibitors [26]. In 
addition to undergoing monoubiquitylation, FANCD2 has 
been shown to be phosphorylated by ATM and ATR further 
highlighting the over lap between these DDR pathways [26, 
64, 67].  
5.3. MCPH1-Dependent Primary Microcephaly 
  Autosomal recessive  Primary Microcephaly, clinically 
characterised by the presence of a severe microcephaly in the 
absence of other overt clinical features, is a genetically het-
erogeneous condition composed of six distinct genetic com-
plementation groups. To date, mutations in four genes, all of 
which encode centrosomal proteins, have been described for 
this disorder (MCPH1, ASPM, CDK5RAP2, CENPJ) [55, 
68-71].  Microcephalin (MCPH1), the first Primary Micro-
cephaly gene identified encodes a BRCT-containing product 
that has been implicated in the response to DSBs [72, 73]. 
Importantly, work using MCPH1-patient derived cell lines 
with hypomorphic mutations in MCPH1 indicated that these 
Table 1.  Mendelian Disorders that Exhibit Microcephaly and Growth Retardation Associated with Defective ATR-Pathway Func-
tion 
Disorder  Mutant Gene  ATR-Dependent Cellular Features 
Seckel syndrome  ATR, PCNT2 and unknown 
Defective ATR-dependent G2-M arrest, supernumerary  
mitotic centrosomes, DFS expression 
Nijmegen breakage syndrome   NBS1  Defective ATR-dependent G2-M arrest 
Fanconi anaemia  FANC-A,B,C,D1,D2,E,F,G,H,M,J  Defective ATR-dependent G2-M arrest, DFS expression 
MCPH1-dependent Primary Microcephaly  MCPH1  Defective ATR-dependent G2-M arrest, supernumerary mitotic centrosomes 140    Current Genomics, 2008, Vol. 9, No. 3  Mark O’Driscoll 
cells are defective in ATR-dependent checkpoint activation 
and also exhibit supernumerary mitotic centrosomes [74]. 
Furthermore, MCPH1 was shown to interact with Chk1, a 
substrate and downstream effector of ATR [74]. 
6. THE IMPACT OF ATR  HAPLOINSUFFICIENCY: 
MURINE STUDIES 
  All of the disorders described so far that collectively ex-
hibit defective ATR-pathway function are all caused by gene 
mutations inherited in an autosomal recessive manner. As 
mentioned earlier, a knockout mouse model for ATR does 
not exist due to early embryonic lethality of ATR
-/- blasto-
cysts [44, 45]. Whilst ATR
+/- animals are viable, re-evalua- 
tion of this murine work suggests that the ATR-DDR path-
way is sensitive to gene copy number variation. Firstly, 
ATR
+/-  mice are not born at the expected Mendelian fre-
quency suggesting a requirement for a full diploid comple-
ment of ATR protein during normal development [75]. Fur-
thermore, decreased survival and increased tumour incidence 
were recorded in the ATR
+/- animals compared to their 
ATR
+/+ counterparts [75]. This is distinct to that of ATM
+/- 
embryos and mice. Heterozygous mutations in ATR  have 
been observed in microsatellite unstable human colorectal 
carcinomas further suggesting that ATR haploinsufficiency 
may play a role in tumourigenesis [76]. In fact, it has been 
suggested that ATR acts as a haploinsufficient tumour sup-
pressor under certain circumstances. Fang and colleagues 
showed that ATR
+/- mice when crossed into a mismatch re-
pair defective (Mlh1
-/-) background (generating ATR
+/-
/Mlh1
-/-) were highly susceptible to embryonic lethality and 
premature tumour development [77]. 
7. THE IMPACT OF ATR  HAPLOINSUFFICIENCY: 
HUMAN STUDIES, INCLUDING THE ASSOCIATION 
OF ATR
+/- WITH A GENOMIC DISORDER 
  Fang and colleagues also showed that haploinsufficiency 
of ATR in human cells results in a clear DDR-defective phe-
notype [77]. Following gene targeting of ATR in the human 
HCT116 colorectal carcinoma cell system, they found a sig-
nificantly increased expression of DFS as well as other gross 
chromosomal rearrangements and amplifications. Further-
more, these ATR
+/- cells exhibited diminished ATR-mediated 
phosphorylation of its effector kinase Chk1. 
  Work from de Ru and colleagues along with that of 
O’Driscoll and colleagues has provided evidence for a cellu-
lar impact of ATR haploinsufficiency associated with a hu-
man genomic disorder [78, 79]. Blepharophimosis-ptosis-
epicanthus inversus syndrome (BPES) is a disorder charac-
terised by a reduction in the dimensions of the palpebral fis-
sures or eye sockets (blepharophimosis), drooping eyelids 
(ptosis) and inverted skin folds originating from the lower 
eyelids (epicanthus inversus) [80]. A variant of this disorder 
is also associated with ovarian failure and female infertility 
[81]. This disorder is caused by autosomal dominant muta-
tions in or heterozygous deletion of FOXL2, a putative fork-
head transcription factor [80]. In a review of the literature, de 
Ru and colleagues noted that most of the BPES patients with 
a cytologically detectable deletion or a microdeletion on 
chromosome 3q, where FOXL2 resides, also exhibited mi-
crocephaly and short stature [78]. These are clinical features 
not typically associated with ‘classical’ BPES. Indeed, it had 
been previously proposed that a putative gene for micro-
cephaly was located close to the BPES-causative gene on 
chromosome 3q (reviewed in [78]). De Ru and colleagues 
mapped the heterozygous deletion in one such BPES patient 
with microcephaly and short stature. They found that this 
patient was haploinsufficient for both FOXL2 and ATR at the 
genomic level. They suggested that the haploinsufficiency of 
ATR may be responsible for the microcephaly and short stat-
ure observed in this patient based on the occurrence of these 
clinical features in ATR-defective Seckel syndrome [78]. In 
a complementary study, O’Driscoll and colleagues subse-
quently showed that cells from this BPES-ATR
+/- patient 
exhibited similar cellular defects to ATR-S cells [79]. These 
cells failed to show significant H2AX formation and Chk1 
phosphorylation following replication fork stalling. They 
also exhibited a similar ATR-dependent G2-M cell cycle 
checkpoint defect to ATR-S cells. Importantly, this pheno-
type was corrected following over-expression of ATR in the 
BPES-ATR
+/- cells. This study reinforced the fact that hap-
loinsufficiency of ATR  has a functional impact in human 
cells but furthermore, that haploinsufficiency of ATR is asso-
ciated with a human genomic disorder that exhibits micro-
cephaly and short stature [79].  
8. HAPLOINSUFFICIENCY OF ATR-PATHWAY 
COMPONENTS IN OTHER GENOMIC DISORDERS 
  Work from Lam and colleagues using tissue-specific 
conditional knockdown in mice of Chk1, an important effec-
tor kinase and substrate of ATR, showed that Chk1 haploin-
sufficiency enhances mammary tumourigenesis [82]. This 
work suggested that an ATR-pathway component and not 
just ATR itself is sensitive to haploinsufficiency. Following 
the cellular characterisation of BPES- ATR
+/-, working on 
the presumption that the ATR-pathway as a whole is sensi-
tive to a reduced gene copy number, O’Driscoll and col-
leagues examined ATR-pathway function in other human 
genomic disorders whose causative genomic deletions were 
known to result in haploinsufficiency of various ATR-
pathway components [79] (Table 2). 
8.1. Isolated Lissencephaly Sequence (ILS) and Miller-
Dieker Lissencephaly Syndrome (MDLS) 
  Normal human brain development involves a rapid and 
sustained cellular proliferation originating from the rostral 
end of the foetal neural tube. Cerebral cortical development 
is achieved via a highly regulated sequence of neuroprogeni-
tor cell division, migration and differentiation.  Platelet-
activating factor acetylhydrolase, isoform B1 (PAHFAH1B1/ 
Lis1), located  on human chromosome 17p13.3, encodes a 
protein, Lissencephaly 1 (Lis1), which plays a central role in 
neuronal migration from the neuroepithelial stem cell layer 
during embryonic brain development [83-85]. Mutations or 
heterozygous deletions of PAHFAH1B1/ Lis1 alone causes 
Isolated Lissencephaly Sequence (ILS), a disorder character-
ised by reduced neuronal migration resulting in a cortical 
surface without significant invaginations, effectively a 
"smooth brain" (lissencephaly) (Fig. 1). Larger deletions 
identified in some ILS patients confer a more severe grade of 
lissencephaly associated with additional craniofacial abnor-
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telomerically from the PAHFAH1B1/Lis1 gene are associ-
ated with Miller-Dieker Lissencephaly Syndrome (MDLS), 
which is characterised by the most severe grade of lissen-
cephaly, craniofacial abnormalities, microcephaly and 
growth retardation (Fig. 1) [14, 86]. Unlike ILS patients, 
ILS+ patients and all MDLS patients are haploinsufficient 
for RPA1, the largest subunit of the Replication Protein A 
complex (Fig. 1) [86]. As described previously, this complex 
coats ssDNA generated for example at a stalled replication 
fork allowing the recruitment and ultimate activation of ATR 
[19]. Similar to what was observed using BPES-ATR
+/- cells, 
cell lines from ILS+ and MDLS patients collectively exhib-
ited compromised ATR-pathway function [79]. Furthermore, 
these cellular defects could be complemented following 
over-expression of RPA1 in these cells. ILS patient cell lines 
with heterozygous deletions in PAHFAH1B1/ Lis1 only, by 
contrast, exhibited a functional ATR-pathway response (Fig. 
1). Therefore, ILS+ and MDLS represent two further human 
genomic disorders with a clinical overlap with ATR-S that 
also exhibits compromised ATR-pathway function at the 
cellular level [79]. 
8.2. Williams-Beuren Syndrome (WBS) 
  WBS is caused by a hemizygous sub-microscopic dele-
tion of 1.55-1.84Mbp on chromosome 7q11.23 encompass-
ing around 25-30 genes. The clinical presentation of this 
condition is multifaceted including craniofacial, endocri-
nological and cardiovascular abnormalities along with mi-
crocephaly and growth retardation [87, 88]. One of the genes 
Table 2.  Genomic Disorders that Exhibit Microcephaly and Growth Retardation Associated with Hemizygous Deletions of ATR 
Pathway Components 
Disorder Chromosome  Deletion  ATR-Pathway Component  ATR-Dependent Cellular Features 
BPES-ATR
+/-  3q23  ATR  Defective ATR-dependent H2AX formation,  
Chk1 phosphorylation and G2-M arrest 
Isolated Lissencephaly Sequence  17p13.3  RPA1  Defective ATR-dependent H2AX formation, 
 Chk1 phosphorylation and G2-M arrest 
Miller-Dieker Lissencephaly Syndrome  17p13.3  RPA1  Defective ATR-dependent H2AX formation,  
Chk1 phosphorylation and G2-M arrest 
Williams-Beuren Syndrome 7q11.23  RFC2  Defective ATR-dependent G2-M arrest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A). Chromosome 17 karyotype from a normal and MDLS individual. B). A view of a single chromatid of chromosome 17p13.3 
showing the order of the genes in this region from the centromere (Cen) to the telomere (Tel). The dotted lines denote the deletions (hemizy-
gous) of various sizes associated with respective patients listed on the left hand side. Con-MR is a patient with a telomeric deletion. This 
patient exhibits mental retardation but normal stature and head circumference. ILS represents an Isolated Lissencephaly Sequence patient 
deleted for PAFAH1B1/Lis1 alone. ILS+ denotes Isolated Lissencephaly Sequence patients with increasing deletions telomeric from 
PAFAH1B1/Lis1. MDLS represents Miller-Dieker Lissencephaly. 142    Current Genomics, 2008, Vol. 9, No. 3  Mark O’Driscoll 
heterozygously deleted in WBS is ELN, which encodes 
elastin, a key structural component of vascular tissues. A 
characteristic cardiovascular abnormality of WBS, supra-
valvular aortic stenosis (narrowing of the ascending aorta), is 
thought to specifically derive from haploinsufficiency of 
ELN [89]. WBS patients are also haploinsufficient for RFC2 
a gene that encodes a component of the Replication Factor C 
(RFC) complex that plays a fundamental role during DNA 
replication loading PCNA onto chromatin, thus facilitating 
DNA polymerase action [90]. RFC2 is also a component of 
the Rad17-RFC2-5 complex that is known to function in the 
DDR [91-94]. In fact, Rad17 is phosphorylated by ATM and 
ATR following DNA damage. Interestingly, a yeast stain (S. 
cerevisae) with a hypomorphic mutation in Rfc2 fails to acti-
vate cell cycle arrest following DNA damage, suggesting 
that the RFC complex and specifically RFC2 plays a direct 
role in the DDR [95]. O’Driscoll and colleagues also showed 
that WBS patient-derived cell lines exhibit a defective ATR-
dependent DDR that could be complemented following re-
introduction of RFC2 into these cells [79]. Therefore, WBS 
represents another genomic disorder that exhibits defective 
ATR-pathway activity wherein microcephaly and growth 
retardation are included in its clinical spectrum [79]. 
  Of course, for all of the genomic disorders discussed 
above that exhibit a defective ATR-dependent DDR associ-
ated with microcephaly and short stature, the occurrence of 
this specific DDR defect with these particular clinical fea-
tures is associative. This association, albeit strong, remains 
an association only. Hence, more work using complementary 
systems such as gene targeting or tissue-specific knockdown 
in the murine system will be required to definitively prove 
the link between ATR-pathway dysfunction and these devel-
opmental abnormalities. 
9. HAPLOINSUFFICIENCY OF OTHER DDR COM-
PONENTS 
  Increasing evidence from murine gene targeting studies 
suggests that haploinsufficiency of various components of a 
diverse distinct range DDR pathways and not just ATR or 
ATR-pathway components has a functional impact on main-
taining genomic stability. For example, haploinsufficiency of 
various components of the mitotic spindle checkpoint such 
BubR1 or MAD2  is associated with aberrant chromosome 
segregation and aneuploidy in mice [96, 97]. Recently, hap-
loinsufficiency of another mitotic spindle checkpoint com-
ponent, Mad1, has been shown to be associated with ane-
uploidy and increased constitutive tumour incidence in 
Mad1
+/- mice compared to their wild-type (Mad1
+/+) litter-
mates [98]. Homologous recombination (HR) is an error-free 
DSB repair pathway used by mammalian cells when a ho-
mologous sister chromatid is available as a template for 
DNA repair (S- and G2-phases of the cell cycle) [99]. Hap-
loinsufficiency of multiple genes whose products function in 
HR results in compromised genomic stability. Specific ex-
amples include Brca1
+/-, Xrcc2
+/-, Xrcc3
+/-, Rad51b
+/- and 
Rad51d
+/-  mice, all of which present with recombination 
deficiency, increased chromosomal aberrations and centro-
somal fragmentation [100-105]. The Mus81-Eme1 complex 
functions as a structure specific endonuclease that plays a 
role in resolving stalling replication forks, 3’-orientated 
DNA flaps/overhangs and nicked HR intermediates [106]. 
Haploinsufficiency of both components of the structure spe-
cific endonuclease Mus81-Eme1 results in increased chro-
mosomal aberrations and a re-replication phenotype in hu-
man and murine cells [107]. Poly(ADP-ribose) polymerase-1 
(PARP-1) catalyzes the covalent attachment of long 
branched poly(ADP-ribose) polymers onto a diverse set of 
target proteins (including itself), using NAD+ as its sub-
strate. Attachment of these negatively charged polymers 
changes the biological activity and properties of the target 
proteins. PARP1 plays an important role in sensing single 
stranded breaks in DNA [108-110]. The level of PARP activ-
ity is sensitive to PARP-1 gene dosage [111]. Interestingly, 
PARP1
-/+ mouse embryonic fibroblasts were shown to ex-
hibit increased supernumerary centrosomes relative to their 
PARP
+/+ counterparts [111]. Furthermore, haploinsufficiency 
of the histone H2A sub-family member H2AX, a known 
ATM and ATR substrate, has been shown to compromise 
genomic integrity, impact on the normal response to DNA 
damage and enhance tumour susceptibility in the absence of 
p53 in mice [112].  
10. IMPLICATIONS OF HAPLOINSUFFICIENCY OF 
DDR COMPONENTS IN HUMAN GENOMIC DISOR-
DERS 
  Murine gene targeting studies have proved invaluable in 
identifying DDR pathways that are sensitive to haploinsuffi-
ciency (e.g. the spindle checkpoint and HR). It is likely that 
haploinsufficiency of these pathways will potentially con-
tribute to the clinical features of known and/or novel ge-
nomic disorders. A major consequence of compromised 
DDR is increased genomic instability and cancer predisposi-
tion (reviewed in [15]). Additionally, since DNA damaging 
agents are the cornerstone of clinically utilised therapeutic 
approaches for cancer, individuals with compromised DDR 
are hypersensitive to such treatments. This has been observed 
in Ataxia telangiectasia, Nijmegen breakage syndrome, LIG4 
syndrome and Fanconi anaemia patients, some of which 
have fatally over-responded to standard radio- and/or chemo-
therapy regimens in the past (reviewed in [113]). Since in-
creased life expectancy due to improved medical supervision 
is now a feature of many genomic disorders, a potentially 
defective DDR may become more important from the per-
spective of tumour development and treatment. This could 
be particularly relevant for genomic disorders with compro-
mised ATR-pathway function. Whilst it is not clear whether 
conditions such as BPES-ATR
+/-, MDLS and WBS represent 
tumour-predisposition conditions, it is clear that they do ex-
hibit a defective ATR-dependent DDR [79]. Provocatively, 
isolated reports of malignancy in these disorders, particularly 
in WBS exit [114-117]. Whether a compromised ATR-
dependent DDR has a role here is currently unclear although 
worthy of deeper investigation. 
  In conclusion, plasticity of the human genome is re-
flected in the high level of CNV observed in clinically nor-
mal individuals. Nevertheless, CNV is causative of many 
pathological conditions in humans. Gene-targeting studies in 
mice have shown that one form of CNV, namely haploinsuf-
ficiency, of certain DDR-pathway components is associated 
with compromised genomic stability. Haploinsufficiency of 
ATR, or some of its pathway components confers similar 
DDR defects to that of ATR-pathway defective Seckel syn-Haploinsufficiency of DNA Damage Response Genes  Current Genomics, 2008, Vol. 9, No. 3    143 
drome cell lines. Furthermore, haploinsufficiency of ATR, 
RPA1 and RFC2 is associated with several human genomic 
disorders that exhibit microcephaly and growth retardation. 
Haploinsufficiency of DDR pathway components is likely to 
contribute to the clinical features of many genomic disor-
ders. This will have implications for the clinical management 
and treatment of these conditions. 
WEB RESOURCES 
  Online Mendelian Inheritance in Man, (http://www.ncbi. 
nlm.nih.gov/Omim), for reviews of the specific genes and all 
of the disorders described here. 
  DECIPHER, (https://decipher.sanger.ac.uk/), a database 
collating multiple genomic imbalances and their associated 
clinical features in human genomic disorders. 
 EUCARUCA,  (http://agserver01.azn.nl:8080/ecaruca/ 
whatisEc.jsp), a database of cytogenetic and clinical data of 
rare chromosomal aberrations from all centres that are mem-
ber of the European Cytogeneticists Association (ECA). 
  Database of Genomic Variants, (http://projects.tcag.ca/ 
variation/), a database listing a comprehensive summary of 
structural variation in the human genome. 
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